EMBER: A Phase 1a/1b Study of LY3484356 Administered as Monotherapy and in Combination With Anticancer Therapies for Patients With ER+ Locally Advanced or Metastatic Breast Cancer and Other Select Non-Breast Cancers
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 379
- 试验地点
- 74
- 主要终点
- Number of Participants with Dose Limiting Toxicities (DLTs) and DLT-Equivalent Toxicities
研究概览
简要总结
The reason for this study is to see if the study drug LY3484356 alone or in combination with other anticancer therapies is safe and effective in participants with advanced or metastatic breast cancer or endometrial cancer.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •All study parts:
- •Participants must be willing to provide adequate archival tissue sample
- •Participants must be willing to use highly effective birth control
- •Participants must have adequate organ function
- •Participants must be able to swallow capsules
- •Dose escalation- Participants must have one of the following:
- •Parts A and B: ER+ HER2- breast cancer with evidence of locally advanced unresectable or metastatic disease who have had the following:
- •Part A: may have had up to 1 prior regimen of any kind for in the advanced/metastatic setting and no prior cyclin-dependent kinase 4/6 (CDK4/6) inhibitor therapy.
- •Part B: may have had up to 2 prior regimens, no more than 1 of which may be endocrine therapy in the advanced/metastatic setting, and must have received a prior CDK4/6 inhibitor
- •Cohort E4: No prior everolimus.
- •Cohort E5: No prior alpelisib and must have a phosphatidylinositol 3-kinase catalytic α (PIK3Cα) mutation as determined by local testing.
- •Part C: ER+, human epidermal growth factor receptor 2 positive (HER2+) breast cancer with evidence of locally advanced unresectable or metastatic disease who have had at least 2 HER2-directed therapies in any setting.
- •Part D: ER+, EEC that has progressed after platinum containing chemotherapy and no prior fulvestrant or aromatase inhibitor therapy.
- •Part E: ER+ and HER2+ breast cancer with evidence of locally advanced, unresectable, or metastatic disease.
- •Part E: Participants must have received induction taxane chemotherapy combined with trastuzumab + pertuzumab as first-line treatment for advanced/metastatic disease and must not have progressed on this regimen.
- •Part E: Participants must not have received more than 1 HER2-directed regimen or any endocrine therapy for advanced disease or any prior CDK4/6 inhibitor therapy.
- •Participants with ER+/HER2- breast cancer enrolled in this study must have had evidence of clinical benefit while on endocrine therapy for at least 24 months in the adjuvant setting or at least 6 months in the advanced/metastatic setting or have untreated de novo metastatic breast cancer
排除标准
- •Participants must not have certain infections such as hepatitis or tuberculosis or HIV that are not well controlled
- •Participants must not have another serious medical condition
- •Participants must not have cancer of the central nervous system that is unstable
- •Participants must not be pregnant or breastfeeding
研究组 & 干预措施
Part B: Dose Expansion: Cohort E4: LY3484356 + Everolimus
LY3484356 and everolimus given orally.
干预措施: Everolimus (Drug)
Part A: Dose Expansion: LY3484356 + Abemaciclib +/- AI
LY3484356 and abemaciclib given orally in combination with or without Aromatase Inhibitor (AI) of physician's choice (Anastrozole, Exemestane, or Letrozole) administered orally.
干预措施: Aromatase Inhibitor (AI) (Drug)
Part B: Dose Expansion: Cohort E3: LY3484356
LY3484356 given orally.
干预措施: LY3484356 (Drug)
Dose Escalation LY3484356
LY3484356 given orally.
干预措施: LY3484356 (Drug)
Part D: Dose Expansion: LY3484356 +/- Abemaciclib
LY3484356 and Abemaciclib given orally with trastuzumab administered intravenously.
干预措施: LY3484356 (Drug)
Part A: Dose Expansion: LY3484356 + Abemaciclib +/- AI
LY3484356 and abemaciclib given orally in combination with or without Aromatase Inhibitor (AI) of physician's choice (Anastrozole, Exemestane, or Letrozole) administered orally.
干预措施: LY3484356 (Drug)
Part A: Dose Expansion: LY3484356 + Abemaciclib +/- AI
LY3484356 and abemaciclib given orally in combination with or without Aromatase Inhibitor (AI) of physician's choice (Anastrozole, Exemestane, or Letrozole) administered orally.
干预措施: Abemaciclib (Drug)
Part B: Dose Expansion: Cohort E4: LY3484356 + Everolimus
LY3484356 and everolimus given orally.
干预措施: LY3484356 (Drug)
Part E: Dose Expansion: LY3484356 + Trastuzumab + Pertuzumab
LY3484356 administered orally in combination with trastuzumab and pertuzumab administered intravenously.
干预措施: LY3484356 (Drug)
Part E: Dose Expansion: LY3484356 + Trastuzumab + Pertuzumab
LY3484356 administered orally in combination with trastuzumab and pertuzumab administered intravenously.
干预措施: Trastuzumab (Drug)
Part B: Dose Expansion: Cohort E5: LY3484356 + Alpelisib
LY3484356 and alpelisib given orally.
干预措施: Alpelisib (Drug)
Part C:Dose Expansion: LY3484356 + Trastuzumab +/- Abemaciclib
LY3484356 administered orally in combination with trastuzumab intravenously with or without Abemaciclib.
干预措施: Trastuzumab (Drug)
Part C:Dose Expansion: LY3484356 + Trastuzumab +/- Abemaciclib
LY3484356 administered orally in combination with trastuzumab intravenously with or without Abemaciclib.
干预措施: LY3484356 (Drug)
Part B: Dose Expansion: Cohort E5: LY3484356 + Alpelisib
LY3484356 and alpelisib given orally.
干预措施: LY3484356 (Drug)
Part C:Dose Expansion: LY3484356 + Trastuzumab +/- Abemaciclib
LY3484356 administered orally in combination with trastuzumab intravenously with or without Abemaciclib.
干预措施: Abemaciclib (Drug)
Part E: Dose Expansion: LY3484356 + Trastuzumab + Pertuzumab
LY3484356 administered orally in combination with trastuzumab and pertuzumab administered intravenously.
干预措施: Pertuzumab (Drug)
Part D: Dose Expansion: LY3484356 +/- Abemaciclib
LY3484356 and Abemaciclib given orally with trastuzumab administered intravenously.
干预措施: Abemaciclib (Drug)
结局指标
主要结局
Number of Participants with Dose Limiting Toxicities (DLTs) and DLT-Equivalent Toxicities
时间窗: Baseline through Cycle 1 (21/28 Day Cycle)
Number of Participants with DLTs and DLT-Equivalent Toxicities
次要结局
- PK: Maximum Concentration (Cmax) of LY3484356(Predose Cycle 1 Day 1 through Predose Cycle 2 Day 1 (21/28 Day Cycles))
- PK: AUC of LY3484356 in Combination with Other Anticancer Therapies(Predose Cycle 1 Day 1 through Predose Cycle 2 Day 1 (21/28 Day Cycles))
- Overall Response Rate (ORR): Percentage of Participants with Confirmed Complete Response (CR) or Partial Response (PR) as per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1(Baseline through Disease Progression or Death (Estimated up to 28 Months))
- Progression Free Survival (PFS): Time From Baseline to the Date of Objective Progression or Death Due to Any Cause, Whichever is Earlier(Baseline to Objective Progression or Death Due to Any Cause (Estimated up to 28 Months))
- Pharmacokinetics (PK): Area Under the Concentration Time Curve (AUC) of LY3484356(Predose Cycle 1 Day 1 through Predose Cycle 2 Day 1 (21/28 Day Cycles))
- Duration of Response (DoR): Time From the Date of First Evidence of CR, PR (per RESIST v1.1) to the Date of Objective Progression or Death Due to Any Cause, Whichever is Earlier(Date of CR or PR to Date of Objective Disease Progression or Death Due to Any Cause (Estimated up to 28 Months))
- Disease Control Rate (DCR): Percentage of Participants with a Best Overall Response (BOR) of CR, PR, and Stable Disease (SD) as per RECIST v1.1(Baseline through Measured Progressive Disease (Estimated up to 28 Months))
- PK: Cmax of LY3484356 in Combination with Other Anticancer Therapies(Predose Cycle 1 Day 1 through Predose Cycle 2 Day 1 (21/28 Day Cycles))
- Clinical Benefit Rate (CBR): Percentage of Participants with a BOR of CR or PR, or SD lasting ≥24 weeks as per RECIST v1.1(Baseline through Measured Progressive Disease (Estimated up to 28 Months))